Targeting the Un-targetable: Initial Treatment of Acute Myeloid Leukemia without Targetable Mutations

<p>Allison Golbach, PharmD, BCPS (<a href='https://twitter.com/AllisonGPharmD'>@AllisonGPharmD</a>) describes epidemiology, pathophysiology, and prognosis of acute myeloid leukemia (AML), reviews literature supporting induction regimens for patients with AML without targetable mutations and discusses how to select between AML induction regimens based on patient-specific factors.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>